However, GPER expression is simultaneous with ERα in some estrogen-responsiveness cancers; as a result, anti-estrogenic compounds must be reconsidered because drugs such as TMX and FVS act as a ligand for GPER [20]. This evidence concerns the gene ESR1 and cancer.